Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H F Dullens

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Immunobiology|July 1, 1993
Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing miceR A Maas, M J Becker, I S Weimar, et al.
Laboratory Animals|April 26, 2000
The VX2 carcinoma in the rabbit auricle as an experimental model for intra-arterial embolization of head and neck squamous cell carcinoma with dextran microspheresR J van Es, O Franssen, H F Dullens, et al.
Invasion & Metastasis|January 1, 1991
Parathymic lymph nodes during growth and rejection of intraperitoneally inoculated tumor cellsH F Dullens, L H Rademakers, S Cluistra, et al.
Cancer Immunology, Immunotherapy : CII|March 31, 1998
Interleukin-2: hope in cases of cisplatin-resistant tumoursM R Bernsen, A W Van Der Velden, L A Everse, et al.
Journal of Leukocyte Biology|October 1, 1986
Tumor growth stimulatory macrophages induced by a subclinical bacterial infection in vivoJ W De Groot, P I Compier-Spies, B Wilbrink, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejectionH F Dullens, R A De Weger, M Van der Maas, et al.
International Immunology|October 1, 1991
Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cellsH F Dullens, J C Wind, R A Maas, et al.
International Journal of Tissue Reactions|January 1, 1982
Staging, growth properties and metastatic behaviour of a transplantable murine T-cell lymphomaH F Dullens, J Hilgers, B J Spit, et al.
International Journal of Cancer|May 28, 1993
Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor-dependent phenomenonM R Bernsen, H J Van Barlingen, A W Van der Velden, et al.
European Journal of Biochemistry|October 1, 1996
Membrane modifications in human erythroleukemia K562 cells during induction of programmed cell death by transforming growth factor beta 1 or cisplatinM Maccarrone, W E Nieuwenhuizen, H F Dullens, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Immunobiology|July 1, 1993
Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing miceR A Maas, M J Becker, I S Weimar, et al.
Laboratory Animals|April 26, 2000
The VX2 carcinoma in the rabbit auricle as an experimental model for intra-arterial embolization of head and neck squamous cell carcinoma with dextran microspheresR J van Es, O Franssen, H F Dullens, et al.
Invasion & Metastasis|January 1, 1991
Parathymic lymph nodes during growth and rejection of intraperitoneally inoculated tumor cellsH F Dullens, L H Rademakers, S Cluistra, et al.
Cancer Immunology, Immunotherapy : CII|March 31, 1998
Interleukin-2: hope in cases of cisplatin-resistant tumoursM R Bernsen, A W Van Der Velden, L A Everse, et al.
Journal of Leukocyte Biology|October 1, 1986
Tumor growth stimulatory macrophages induced by a subclinical bacterial infection in vivoJ W De Groot, P I Compier-Spies, B Wilbrink, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejectionH F Dullens, R A De Weger, M Van der Maas, et al.
International Immunology|October 1, 1991
Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cellsH F Dullens, J C Wind, R A Maas, et al.
International Journal of Tissue Reactions|January 1, 1982
Staging, growth properties and metastatic behaviour of a transplantable murine T-cell lymphomaH F Dullens, J Hilgers, B J Spit, et al.
International Journal of Cancer|May 28, 1993
Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor-dependent phenomenonM R Bernsen, H J Van Barlingen, A W Van der Velden, et al.
European Journal of Biochemistry|October 1, 1996
Membrane modifications in human erythroleukemia K562 cells during induction of programmed cell death by transforming growth factor beta 1 or cisplatinM Maccarrone, W E Nieuwenhuizen, H F Dullens, et al.
Pageof 7